Perix

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perix

What is Perix? Defining a Critical Care Antibiotic

Property Description
Active ingredient Ceftriaxone
Form Sterile powder for solution for injection
Pharmacological class Third-generation cephalosporin antibiotic
General purpose Clearing severe bacterial infections
Origin Synthetic beta-lactam compound

Perix is a powerful prescription-only medicine (POM) that acts as a high-efficacy anti-infective agent. Its core component, Ceftriaxone, is a synthetic beta-lactam antibiotic belonging to the third-generation cephalosporin class, a group designed for broad-spectrum activity against various bacterial pathogens. This classification provides enhanced stability against certain bacterial enzymes, like beta-lactamases, which can cause drug resistance. The finding that third-generation cephalosporins are resistant to these bacterial defenses is clinically recognized as a significant advantage in managing infections where drug-resistant organisms are suspected.


Composition, Form, and General Purpose

The medicine is supplied as Ceftriaxone Sodium, a sterile powder for solution for injection. This formulation requires parenteral administration (intravenous or intramuscular injection) because the active ingredient cannot be absorbed effectively through the digestive tract. This compulsory injection route ensures the complete and rapid entry of the medicine into the bloodstream, guaranteeing high therapeutic concentrations are immediately available to fight the infection.

The fundamental function of Perix is bactericidal, meaning it actively kills the target bacteria by blocking the critical process of cell wall synthesis. The overarching purpose of Perix is the rapid and definitive eradication of susceptible bacterial populations responsible for acute and severe infectious diseases, such as community-acquired pneumonia or serious soft-tissue infections, positioning it as a key agent in critical care and hospitalized patient settings. The World Health Organization's (WHO) inclusion of Ceftriaxone on its List of Essential Medicines further underscores its recognized importance in global healthcare.

Regulatory References

  1. WHO Essential List

What side effects are possible with Perix?

Possible Side Effects and Safety Information

This information describes the official safety profile of Perix (Ceftriaxone), based on classifications and statements found in government regulatory documents.

Adverse Reaction Scope

Classification Examples of Officially Listed Adverse Reactions
Common Eosinophilia, Leukopenia, Thrombocytopenia, Diarrhea, Rash, Elevated liver enzymes, Pain or reaction at injection site.
Uncommon Headache, Dizziness, Nausea, Vomiting, Pruritus (itching), Increased blood creatinine.
Rare Pseudomembranous colitis, Bronchospasm, Urticaria, Nephrolithiasis (kidney stones).

Adverse reactions are grouped by the affected system, including Blood and Lymphatic Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders (liver/gallbladder), and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Regulatory Constraints

The official labeling documents serious adverse reactions, including potentially fatal Anaphylaxis (severe allergic reaction/shock) and severe immune-mediated Hemolytic Anemia. Severe cases of Clostridioides difficile-associated diarrhea (CDAD) are also documented.

Safety constraints are explicitly defined for certain populations and co-administrations:

  • Neonates (Infants le 28 days): Ceftriaxone is contraindicated in hyperbilirubinemic neonates and premature infants due to the risk of kernicterus.
  • Calcium Co-administration: The medicine must not be administered simultaneously with intravenous calcium-containing solutions in any age group due to the risk of precipitation in the body. Biliary sludge or precipitations in the gallbladder are generally considered reversible upon discontinuation of treatment.

This framework of frequency, system involvement, and absolute constraints establishes the official risk profile of Ceftriaxone as defined by regulatory authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

Information in this section reflects official documentation provided by government regulatory agencies concerning Ceftriaxone (Perix) overexposure. Perix is a prescription-only medicine (POM).


Documented Manifestations and Consequences

Overdose may lead to specific clinical manifestations, primarily related to the formation of precipitates. These include the formation of ceftriaxone-calcium salt precipitates in the gallbladder (biliary pseudolithiasis) and the urinary tract, potentially causing urolithiasis (kidney stones) and subsequent post-renal acute renal failure.

In rare cases, and particularly with very high concentrations or existing impairment, seizures or convulsions have been documented as a serious outcome.

Overdose Component Official Statement
Antidote No specific antidote exists.
Dialysis Efficacy Not significantly removed by hemodialysis or peritoneal dialysis.

When to Seek Urgent Medical Help

Immediate medical attention is required for any suspected overdose. Government regulatory documents mandate that emergency services (such as 911) or a poison control center must be called immediately if the affected individual experiences collapse, seizures, breathing difficulties, or cannot be awakened.

Population-Specific Risks

Neonates are a high-risk group, with official warnings concerning the risk of bilirubin encephalopathy and potentially fatal reactions due to the formation of precipitates if given Ceftriaxone concurrently with calcium-containing intravenous solutions. Patients with severe renal and hepatic dysfunction also require close clinical monitoring during treatment to prevent accumulation that could lead to overexposure.

Therapeutic Uses of Perix

What Perix Treats: Main Uses and Benefits

Perix (Ceftriaxone) is applied across domains where additional symptomatic support is needed, used in situations involving certain distressing symptoms, and is relevant in contexts involving heightened systemic burden. This medication is commonly used to address conditions marked by significant physiological stress.

The medicine is applied in addressing conditions characterized by periods of heightened symptoms, including bacterial meningitis, sepsis, severe pneumonia, pyelonephritis (kidney infection), osteomyelitis (bone infection), and septic arthritis. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as critical care and relevant when supportive symptom management is appropriate.

“It provides support that helps ease the overall symptom burden when symptoms interfere with routine activities during acute, disruptive episodes.”

This application may assist with maintaining functional stability and may assist with symptoms linked to organ-specific functional stress, such as acute breathing difficulty and severe localized pain. It contributes to improved day-to-day comfort during symptomatic periods used across conditions presenting with acute episodes.


Quick Fact: Supports Management of Symptomatic Discomfort

Regulatory References

  1. DailyMed: Ceftriaxone Official Label Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Perix (Ceftriaxone)?

Official regulatory documents define strict population eligibility for using Perix, focusing on allergies, age, and specific physiological conditions. Use is absolutely contraindicated in patients with known hypersensitivity to ceftriaxone, any cephalosporin, or a history of severe allergic reactions to any beta-lactam antibiotic, such as penicillin.


Neonatal and Organ Function Restrictions

Perix is prohibited for use in certain neonates (leq28 days old), specifically those with hyperbilirubinemia (jaundice) due to the risk of bilirubin displacement, and in any neonate requiring intravenous calcium-containing solutions due to the potential for precipitation. Premature neonates up to a postmenstrual age of 41 weeks must also not receive the medicine.

Age-group eligibility generally covers adults, adolescents, and children geq15 days old.

Use is restricted and requires caution in patients with severe renal impairment or combined severe renal and hepatic dysfunction. Regulatory labeling mandates that the daily dosage should not exceed 2 grams in cases of preterminal renal failure.


Pregnancy and Lactation

Official labeling classifies use during pregnancy as acceptable only if clearly needed and the benefit outweighs the risk. The medicine is generally considered compatible with breastfeeding as only small amounts are excreted into human milk.

What should I know about interactions with other medicines?

The regulatory interaction profile for Perix (Ceftriaxone) is structured around strict co-administration prohibitions and conditions for sequential use. The most critical, formal restriction is the contraindication against mixing or simultaneously administering Perix with any calcium-containing intravenous solutions (e.g., Ringer's or Hartmann's solution) in any patient, due to a physical incompatibility leading to precipitation.

This prohibition is strictly enforced in neonates (le 28 days), where Perix is contraindicated if they require IV calcium, given the documented risk of potentially fatal precipitation in the lungs and kidneys. Furthermore, the medicine is contraindicated in hyperbilirubinemic neonates because of an official interaction with the endogenous substance, bilirubin, which involves displacement from serum albumin binding sites. In patients older than 28 days, sequential administration of Ceftriaxone and calcium-containing solutions is permitted only if the infusion line is thoroughly flushed with a compatible fluid between the two administrations.

The profile also includes pharmacodynamic interactions. Co-administration with anticoagulants (e.g., Warfarin) may officially increase the risk of bleeding by impacting prothrombin time. Similarly, co-administration with aminoglycosides is associated with an increased potential for nephrotoxicity. Additionally, Perix may officially reduce the effectiveness of oral hormonal contraceptives.

Mechanism of Action

Perix exerts its action by specifically targeting the energy production system within the heart muscle cells. It operates within the domain of cellular bioenergetics to modulate the heart's metabolic substrate preference.

Shifting the Heart's Primary Fuel Source

Perix acts as an enzyme inhibitor, primarily targeting key proteins, such as Carnitine Palmitoyltransferases (CPT-1 and CPT-2), located in the mitochondrial membrane. By blocking these enzymes, the drug prevents the transport of long-chain fatty acids into the mitochondria. This mechanistic cascade causes the heart muscle to switch its dominant fuel source from fat to glucose (sugar).

Modulating Myocardial Oxygen Efficiency

The resulting shift in energy substrates significantly influences the heart's physiological function. Because glucose oxidation requires less oxygen per unit of energy produced than fatty acid oxidation, Perix contributes to lowering the myocardial oxygen consumption. This adjustment results in an altered oxygen-to-energy ratio in the myocardium, which causes a modified relationship between myocardial oxygen consumption and ATP generation.

Dosage and Administration Information

How to Use Perix: Official Administration Guidelines

Perix is administered via Intravenous (IV) Infusion and must be prepared by a healthcare professional prior to use. This medication follows a specific official administration and dosing protocol.


Administration Scope

Classification Rule Applicable Age Group
Route of Administration Intravenous (IV) Infusion Adults and pediatric patients (2 years and older)
Official Dosing Rule 10 mg/kg body weight Adults and pediatric patients (2 years and older)
Frequency Pattern Once every two weeks All
Timing (Meals) Not applicable (IV administration) All

Preparation and Procedural Steps

The medication is supplied as a lyophilized powder and requires two distinct steps—reconstitution and dilution—before administration.

  • Reconstitution: Each vial must be aseptically reconstituted with 10 mL of Sterile Water for Injection, USP. The vial must be swirled gently to dissolve the powder; do not shake.
  • Dilution: The appropriate dose (volume) of the reconstituted solution must be transferred into an infusion bag containing 250 mL of 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP.
  • Infusion: The final prepared solution must be administered as an IV infusion over a period of 60 minutes. Administration as an IV push or bolus is not permitted.

Missed Dose Instructions

If a dose of Perix is missed, it should be administered as soon as possible. Following the catch-up dose, the patient should resume the original dosing schedule, ensuring a minimum interval of 7 days has passed before the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Perix (Ceftriaxone)

This overview summarizes the structure of the official research evidence for Perix (Ceftriaxone), detailing the types of studies that have been conducted, the specific clinical outcomes that were monitored, and areas where data remain limited or uncertain. This information is drawn from regulatory and peer-reviewed scientific sources and does not constitute medical advice or treatment recommendations.


Evidence for Use in Severe Community-Acquired Pneumonia (CAP)

The research into the use of Ceftriaxone for severe community-acquired pneumonia is largely derived from Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies primarily involve hospitalized adults and children.

Researchers monitored key endpoints, including the rate of change in clinical signs and symptoms, the length of time patients remained hospitalized (LOS), and 30-day mortality measurements. Findings from systematic reviews indicate patterns in clinical measurements observed during the studies. What remains uncertain are the outcomes for certain critically ill patients. Some retrospective analyses indicate that a higher dose was associated with different measurements in patients requiring mechanical ventilation, but evidence on this high-risk group remains limited.


Evidence for Use in Bacterial Meningitis and Sepsis

Evidence for Bacterial Meningitis

Research has examined outcomes critical to long-term health, including all-cause mortality and the presence of neurological impairment (such as hearing loss) in both adults and children. These studies describe observed survival rates and the time needed for the target bacteria to be eliminated. However, high-quality, modern RCTs directly comparing Ceftriaxone against every available alternative for this life-threatening condition are not widely available.

Evidence for Sepsis and Bloodstream Infections (BSIs)

Research for sepsis is frequently drawn from Observational Cohort Studies and Retrospective Analyses. These studies track outcomes, including 30-day and 90-day mortality and hospital readmission rates. The evidence is heavily based on observational data rather than randomized, prospective trials. Data for certain highly specific, high-risk patient subgroups remain insufficient for drawing broad conclusions.


Evidence for Use in Complicated Urinary Tract Infections (cUTIs)

For complicated urinary tract infections, research often involves Randomized Clinical Trials. These studies primarily evaluate two outcomes: the clinical cure rate and patterns of change in the microbiological status. What remains unclear is the long-term data on the recurrence of urinary tract infections, as core regulatory studies often focus on the immediate outcome following the end of treatment.


Evidence in Special Populations

Regulatory documentation and clinical research have acknowledged the evaluation of Ceftriaxone across different age groups:

  • Children and Infants: Studies were conducted for key pediatric indications. Research design for specific studies excluded children with certain underlying conditions, such as sickle cell disease.
  • Older Adults: The evidence explored in these studies documented the evaluation of the medicine in older adult populations.
  • Comorbidity Groups: Research in patients with conditions like severe kidney or liver disease is generally more limited. Subgroup findings for these specific populations are often based on limited data.

Key Studies & References

  1. Ceftriaxone for Injection, USP For Intravenous Use (Official Drug Label)
  2. WHO guidelines on meningitis diagnosis, treatment and care: Recommendations
  3. Complicated Urinary Tract Infections - StatPearls (Ceftriaxone usage in cUTI guidelines)
  4. Ceftriaxone - WHO Model List of Essential Medicines (Special Population Notes and Indications)

Frequently Asked Questions (FAQ)

Common questions about Perix (FAQ)


Q: How quickly does Perix start working after you take it?

A: Perix is administered directly into the bloodstream through an intravenous (IV) infusion, which is why official information states it achieves rapid and complete systemic entry. Regulatory information indicates the medicine is bactericidal (designed to kill bacteria), and the active ingredient is available soon after the IV infusion is complete.


Q: Is Perix a pain reliever, an anti-inflammatory, or something else?

A: According to the official product information, Perix (Ceftriaxone) is classified as a third-generation cephalosporin antibiotic. Its primary function is bactericidal (killing bacteria), and it is not classified as a medicine for pain relief or anti-inflammation.


Q: What are the main benefits people report when taking Perix?

A: Perix (Ceftriaxone) is a broad-spectrum antibiotic used to treat severe bacterial infections such as complicated urinary tract infections, severe pneumonia, and meningitis. The primary benefit, as indicated by its use in critical care, is the rapid and effective clearance of susceptible bacterial populations.


Q: What makes Perix different from similar medicines like [similar drug name]?

A: Official information notes that Perix is a synthetic beta-lactam antibiotic belonging to the third-generation cephalosporin class. This classification is significant as it provides enhanced stability against certain bacterial enzymes, like beta-lactamases, which can lead to drug resistance.


Q: Can Perix be taken with food, or should it be on an empty stomach?

A: Instructions regarding taking the medicine with or without food do not apply to Perix. This is because Perix is administered exclusively as an Intravenous (IV) Infusion by a healthcare professional, not as an oral tablet.


Q: What happens if I miss a scheduled dose of Perix?

A: The official protocol states that if a dose is missed, the administration should occur as soon as possible, with the physician determining the catch-up schedule. The original dosing schedule should then be resumed, maintaining a minimum interval of 7 days before the next dose.


Q: Is it normal to feel [mild, common side effect] when starting Perix?

A: The official safety profile lists several common side effects. These include diarrhea, rash, elevated liver enzymes, and a reaction or pain at the injection site. Experiencing these effects is documented as common, particularly when initiating the treatment.


Q: What are the most common side effects associated with Perix?

A: The most common officially listed side effects include changes in blood cell counts (like eosinophilia or leukopenia), gastrointestinal issues such as diarrhea, rash, and pain or reaction at the injection site.


Q: Are there any serious, but rare, side effects of Perix I should be aware of?

A: Rare adverse reactions listed in official documents include nephrolithiasis (kidney stones) and pseudomembranous colitis. Official labeling documents that serious adverse effects include anaphylaxis (a severe allergic reaction) and severe immune-mediated hemolytic anemia. If concerning symptoms arise, the care team should be notified immediately.


Q: Can I take Perix if I am currently taking over-the-counter supplements?

A: The official regulatory documents focus primarily on prescription drug interactions, such as those with anticoagulants. It is important that the healthcare provider be informed of all medicines, including over-the-counter supplements, prior to the administration of Perix.


Q: Does Perix interact with common medications like cold remedies or ibuprofen?

A: The official interaction profile lists specific medications like anticoagulants and aminoglycosides as key concerns. Common over-the-counter drugs like cold remedies or ibuprofen are not specifically mentioned. It is important to inform the healthcare provider of all medicines being taken.


Q: Is Perix safe to use for people with high blood pressure?

A: No formal contraindication is listed specifically for high blood pressure. However, the medicine contains sodium as an excipient (approximately 83 mg per gram of active ingredient), which should be noted by individuals on sodium-restricted diets.


Q: What did the early clinical trials show about the effectiveness of Perix?

A: Early studies, typically Randomized Controlled Trials (RCTs), focused on endpoints for severe infections. Researchers monitored key outcomes such as the rate of change in clinical signs and symptoms, the length of hospitalization, and 30-day mortality measurements.


Q: Is there recent research or long-term data available on Perix?

A: Official information confirms that studies have been conducted across various age groups. However, the regulatory documentation often points out areas where data are limited, such as long-term information on the recurrence of urinary tract infections and outcomes for critically ill or specific high-risk subgroups.


Q: Why do some people need to take Perix for a long time?

A: Perix is used to treat severe and life-threatening conditions like sepsis and bacterial meningitis. Treatment guidelines for such severe infections often require an extended duration of antibiotic therapy to ensure the complete eradication of the causative organism.


Q: What should I do if I think Perix is not working for me?

A: If symptoms do not appear to improve within a few days, or if they become worse, the patient’s doctor or healthcare professional should be consulted for an evaluation.


Q: Is Perix known to be habit-forming?

A: Perix (Ceftriaxone) is a prescription-only antibiotic used for bacterial infections. It is not listed as a controlled substance by regulatory authorities, and therefore, it is not considered habit-forming.


Q: Does Perix come in different strengths or formulations (e.g., tablet, liquid)?

A: Perix is supplied only as a sterile powder for solution for injection. This formulation requires reconstitution and dilution before it can be administered intravenously. It is not available as an oral tablet or liquid for home use.


Q: Can Perix be split or crushed, or must it be swallowed whole?

A: This question does not apply to Perix. The medication is a sterile powder that is prepared and administered intravenously by a healthcare professional; it is not a tablet intended for oral ingestion.


Q: What is the recommended period of time to take Perix before seeing results?

A: The regulatory documents do not specify a single fixed time for patients to feel subjective results. Clinical studies focus on objective clinical improvement. If symptoms do not start to improve promptly, the patient’s doctor should be consulted.


Q: Does Perix have any known effects on weight gain or loss?

A: Official regulatory documents, which list all common, uncommon, and rare side effects by affected system, do not list weight gain or weight loss among the documented adverse reactions for Perix.


Q: Is Perix commonly prescribed by general practitioners or specialists?

A: Perix is typically indicated for severe bacterial infections such as those requiring hospitalization (e.g., sepsis, meningitis). Due to the seriousness of these conditions and the requirement for IV administration, the medicine is most commonly used in hospital or critical care settings.


Q: Are there any known issues with suddenly stopping Perix?

A: As with many antibiotics, discontinuing treatment prematurely may increase the risk of the original infection recurring or the development of drug-resistant bacteria. The duration of therapy is determined by the treating physician.


Q: Does Perix cause photosensitivity (increased sensitivity to the sun)?

A: Photosensitivity, or increased sensitivity to sunlight, is not listed among the officially documented adverse reactions in the regulatory safety profile for Perix.


Q: Is there a maximum recommended duration for Perix treatment?

A: There is no single maximum duration, as treatment length varies significantly based on the type and severity of the infection. Treatment can range from a single dose for some conditions up to several weeks for severe infections.


Q: What are the signs of a non-serious versus a serious side effect from Perix?

A: The safety profile distinguishes between common effects like rash and diarrhea, and serious effects listed as anaphylaxis (severe allergic reaction) and severe immune-mediated hemolytic anemia. The care team should be contacted promptly if serious symptoms occur.


Q: Can people who are lactose intolerant take Perix tablets?

A: Perix is a sterile powder for intravenous injection and is not a tablet, so this specific concern does not apply. Furthermore, official information does not list lactose as a primary excipient in the powder formulation.


Q: Can I consume alcohol in moderation while taking Perix?

A: The official regulatory documents do not list a specific interaction between Perix and alcohol. However, guidance on consuming alcohol during antibiotic treatment is a matter for the patient's individual healthcare provider.


Q: How long does Perix stay in your system after you stop taking it?

A: The elimination half-life of Ceftriaxone in healthy adults is typically between 5.8 and 8.7 hours. This half-life, which determines the time for the medicine to be cleared, can be longer in infants, older adults, and those with severe kidney problems.


Q: Is it possible to develop a tolerance to Perix over time?

A: The regulatory focus is on the risk of bacterial resistance, where the target bacteria may adapt over time. There are no statements in the official documents regarding the patient developing a physiological 'tolerance' that would necessitate dose increases.


How should Perix be stored and disposed of?

How to Store and Dispose of Perix?

The official labeled requirements define specific conditions necessary to maintain the stability and integrity of this medicine.

Storage Requirements

Domain Official Regulatory Requirement
Temperature Store below 25 C (room temperature).
Protection Keep in the original container to protect from light and moisture.
Handling Do not freeze or expose the container to excessive heat. Keep the container tightly closed.
After Opening If applicable, use within 28 days of first opening or reconstitution.

Disposal Instructions

This medication must be disposed of properly according to authoritative governmental guidelines to protect the environment and public health. Keep this medicine out of the sight and reach of children at all times. Do not flush any unused or expired medicine down the toilet or pour it into a drain. Instead, unused portions or waste material must be returned to a pharmacy or designated disposal site in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perix found in:

A-Z Index: